Protalix Biotherapeutics (PLX) revenue and earnings history
Protalix Biotherapeutics reported revenue of $52.7M for fiscal 2025 (year ended Dec 31, 2025), −1.2% on the year before, and net income of −$6.6M.
Over 16 years, from fiscal 2009 to fiscal 2025, revenue grew at a compound rate of +35.9% a year.
Revenue and net income, 17 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $52.7M−1.2% | −$5.5M | −$6.6M | −$12M | $1.64M | −$13.6M | $2.3M | — | — | $14.7M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Protalix Biotherapeutics (PLX) on OQRO.
Common questions
What was Protalix Biotherapeutics's revenue in fiscal 2025?
$52.7M for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 18, 2026. That is −1.2% on fiscal 2024 ($53.4M).
How fast has Protalix Biotherapeutics's revenue grown?
From $388K in fiscal 2009 to $52.7M in fiscal 2025: a compound annual growth rate of +35.9% over 16 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Protalix Biotherapeutics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.